Coherus Oncology, Inc. (CHRS) financial statements and ratios from SEC XBRL: revenue $42.17M (TTM), net margin 398.4%, revenue growth -84.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $42.17M |
| Net Margin | 398.4% |
| Revenue Growth (YoY) | -84.2% |
| EPS Growth (YoY) | 472.0% |
| Price / Book | 3.58 |
| Price / Sales | 4.31 |
| Altman Z-Score | -8.69 (distress) |
| Sector P/E (Healthcare) | 21.7 |
CHRS overview · CHRS earnings · CHRS KPIs · CHRS investor relations · CHRS ownership · CHRS peers · CHRS filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.